- Home
- FINS vs GUTS Comparison
FINS vs GUTS Comparison
Compare FINS & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINS
- GUTS
- Stock Information
- Founded
- FINS 2019
- GUTS 2010
- Country
- FINS United States
- GUTS United States
- Employees
- FINS N/A
- GUTS N/A
- Industry
- FINS Finance/Investors Services
- GUTS
- Sector
- FINS Finance
- GUTS
- Exchange
- FINS Nasdaq
- GUTS NYSE
- Market Cap
- FINS 323.3M
- GUTS 110.1M
- IPO Year
- FINS N/A
- GUTS 2024
- Fundamental
- Price
- FINS $12.78
- GUTS $1.79
- Analyst Decision
- FINS
- GUTS Buy
- Analyst Count
- FINS 0
- GUTS 2
- Target Price
- FINS N/A
- GUTS $18.00
- AVG Volume (30 Days)
- FINS 78.0K
- GUTS 292.2K
- Earning Date
- FINS 01-01-0001
- GUTS 02-02-2025
- Dividend Yield
- FINS 9.97%
- GUTS N/A
- EPS Growth
- FINS N/A
- GUTS N/A
- EPS
- FINS N/A
- GUTS N/A
- Revenue
- FINS N/A
- GUTS $97,000.00
- Revenue This Year
- FINS N/A
- GUTS N/A
- Revenue Next Year
- FINS N/A
- GUTS N/A
- P/E Ratio
- FINS N/A
- GUTS N/A
- Revenue Growth
- FINS N/A
- GUTS N/A
- 52 Week Low
- FINS $11.61
- GUTS $1.74
- 52 Week High
- FINS $12.57
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- FINS 45.94
- GUTS 36.46
- Support Level
- FINS $12.82
- GUTS $2.00
- Resistance Level
- FINS $13.11
- GUTS $2.13
- Average True Range (ATR)
- FINS 0.11
- GUTS 0.20
- MACD
- FINS -0.01
- GUTS -0.05
- Stochastic Oscillator
- FINS 31.63
- GUTS 4.76
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.